Related resources and publications
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
BRGSF-HIS mice as a predictive tool for safety assessment of biologics
BRGSF-HIS for safety assessment
Sep 2024
(Macomics) Discovery of MACO355: a first in mechanism ligand-blocking independent LILRB1/2/3 antibody for cancer therapy
In vivo tumor growth suppression
Apr 2024
Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in BRGSF-HIS mice
BRGSF-HIS & tumor microenvironment
Apr 2024
Cell-depleting agents assessment in preclinical models
BRGSF-HIS & hFcγR to assess cell depletion
Nov 2023
Myeloid cells' contribution is key in CRS pathophysiology induced by T-cell engagers in BRGSF-HIS model
BRGSF-HIS & myeloid cell compartment in CRS
Nov 2023
Functional human myeloid cells in BRGSF-HIS humanized mice enable myeloid-directed therapy assessment
BRGSF-HIS for myeloid-directed therapy assessment
Apr 2023
CD3 humanized mouse models as validated tools to assess immune-related adverse events of T-cell engagers
CD3 and BRGSF-HIS to assess IrAEs
Nov 2022
Anti-VISTA agents profiling: complementarity of BRGSF-HIS and hVISTA Knock-in as preclinical models for immunotherapies
BRGSF-HIS & hVISTA for immunotherapies
Nov 2022
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response
Nat Commun
Apr 2024
Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model
Front Immunol
Feb 2024
Staphylococcus aureus Panton-Valentine Leukocidin worsens acute implant-associated osteomyelitis in humanized BRGSF mice
JBMRplus
Jan 2024
No results
